| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinocerebellar Ataxias | 58 | 2025 | 85 | 14.870 |
Why?
|
| Calcium Channels | 16 | 2019 | 182 | 4.530 |
Why?
|
| Cerebellum | 19 | 2023 | 250 | 2.800 |
Why?
|
| Myasthenic Syndromes, Congenital | 11 | 2014 | 36 | 2.460 |
Why?
|
| Friedreich Ataxia | 15 | 2024 | 15 | 2.410 |
Why?
|
| Postural Balance | 6 | 2024 | 49 | 2.320 |
Why?
|
| Trinucleotide Repeat Expansion | 14 | 2024 | 24 | 2.020 |
Why?
|
| Purkinje Cells | 10 | 2024 | 85 | 2.020 |
Why?
|
| Internal Ribosome Entry Sites | 5 | 2019 | 16 | 1.980 |
Why?
|
| Muscle, Skeletal | 8 | 2013 | 473 | 1.840 |
Why?
|
| Receptors, Cholinergic | 19 | 2011 | 77 | 1.750 |
Why?
|
| Neuromuscular Junction | 16 | 2014 | 81 | 1.660 |
Why?
|
| Disease Progression | 21 | 2024 | 1486 | 1.560 |
Why?
|
| Ataxia | 8 | 2023 | 42 | 1.490 |
Why?
|
| Spinocerebellar Degenerations | 11 | 2022 | 19 | 1.490 |
Why?
|
| Severity of Illness Index | 20 | 2025 | 1882 | 1.450 |
Why?
|
| Age of Onset | 15 | 2024 | 319 | 1.440 |
Why?
|
| Cerebellar Ataxia | 10 | 2023 | 24 | 1.440 |
Why?
|
| Calcium Channels, N-Type | 5 | 2019 | 17 | 1.230 |
Why?
|
| Calpain | 4 | 2013 | 113 | 1.190 |
Why?
|
| Speech | 4 | 2021 | 85 | 1.140 |
Why?
|
| Motor Endplate | 10 | 2013 | 31 | 1.020 |
Why?
|
| Humans | 137 | 2025 | 90640 | 1.010 |
Why?
|
| Mutation | 16 | 2021 | 4183 | 0.950 |
Why?
|
| MicroRNAs | 4 | 2022 | 561 | 0.920 |
Why?
|
| Myasthenia Gravis | 14 | 1998 | 83 | 0.890 |
Why?
|
| Transcription Factors | 4 | 2022 | 1670 | 0.890 |
Why?
|
| Video Recording | 1 | 2025 | 204 | 0.870 |
Why?
|
| Synaptic Transmission | 6 | 2012 | 229 | 0.850 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2018 | 59 | 0.820 |
Why?
|
| Peptides | 7 | 2013 | 661 | 0.820 |
Why?
|
| Male | 79 | 2025 | 42967 | 0.810 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 2 | 2012 | 17 | 0.780 |
Why?
|
| Exome | 3 | 2021 | 131 | 0.770 |
Why?
|
| Middle Aged | 58 | 2025 | 26347 | 0.750 |
Why?
|
| Adult | 59 | 2025 | 26953 | 0.740 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 253 | 0.710 |
Why?
|
| Female | 75 | 2025 | 46894 | 0.690 |
Why?
|
| Gene Expression Regulation | 7 | 2018 | 1991 | 0.660 |
Why?
|
| Animals | 47 | 2022 | 27715 | 0.660 |
Why?
|
| Mice, Transgenic | 14 | 2022 | 1583 | 0.650 |
Why?
|
| Calcium Signaling | 3 | 2011 | 139 | 0.630 |
Why?
|
| Elongation Factor 2 Kinase | 2 | 2021 | 7 | 0.600 |
Why?
|
| Calcium Channels, L-Type | 1 | 2018 | 38 | 0.590 |
Why?
|
| Aged | 37 | 2025 | 19424 | 0.580 |
Why?
|
| Mice | 25 | 2022 | 11949 | 0.580 |
Why?
|
| RNA, Messenger | 5 | 2022 | 2034 | 0.570 |
Why?
|
| Calcium | 7 | 2011 | 1183 | 0.560 |
Why?
|
| Muscle Fibers, Skeletal | 3 | 2006 | 51 | 0.560 |
Why?
|
| HEK293 Cells | 5 | 2019 | 660 | 0.550 |
Why?
|
| Exons | 3 | 2018 | 453 | 0.550 |
Why?
|
| Disease Models, Animal | 17 | 2020 | 2409 | 0.540 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 21 | 0.540 |
Why?
|
| Caspase 9 | 2 | 2013 | 49 | 0.540 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2016 | 37 | 0.530 |
Why?
|
| Brain | 7 | 2024 | 2328 | 0.530 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2016 | 101 | 0.520 |
Why?
|
| Caspase 3 | 2 | 2013 | 162 | 0.520 |
Why?
|
| Ocular Motility Disorders | 3 | 2015 | 16 | 0.510 |
Why?
|
| Acetylcholine | 3 | 2013 | 177 | 0.480 |
Why?
|
| Reproducibility of Results | 7 | 2025 | 2782 | 0.480 |
Why?
|
| Metalloendopeptidases | 1 | 2015 | 44 | 0.480 |
Why?
|
| Protein Biosynthesis | 2 | 2016 | 390 | 0.480 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 667 | 0.470 |
Why?
|
| Patch-Clamp Techniques | 10 | 2014 | 397 | 0.460 |
Why?
|
| Point Mutation | 8 | 2012 | 246 | 0.460 |
Why?
|
| Machado-Joseph Disease | 4 | 2023 | 8 | 0.450 |
Why?
|
| Caspase 7 | 1 | 2013 | 15 | 0.440 |
Why?
|
| Protein Subunits | 4 | 2006 | 123 | 0.430 |
Why?
|
| Sequence Analysis, DNA | 4 | 2018 | 872 | 0.430 |
Why?
|
| Conserved Sequence | 2 | 2012 | 211 | 0.400 |
Why?
|
| Neuromuscular Diseases | 2 | 2006 | 31 | 0.400 |
Why?
|
| Extremities | 1 | 2013 | 176 | 0.390 |
Why?
|
| Transfection | 7 | 2020 | 910 | 0.390 |
Why?
|
| Muscle Weakness | 2 | 2002 | 62 | 0.380 |
Why?
|
| Motor Neurons | 1 | 2013 | 177 | 0.380 |
Why?
|
| Nitric Oxide | 1 | 2013 | 281 | 0.380 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2011 | 29 | 0.380 |
Why?
|
| Retinitis Pigmentosa | 1 | 2011 | 35 | 0.380 |
Why?
|
| Neurology | 2 | 2006 | 75 | 0.380 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2011 | 22 | 0.380 |
Why?
|
| DNA Damage | 1 | 2013 | 374 | 0.370 |
Why?
|
| Spasms, Infantile | 1 | 2011 | 35 | 0.370 |
Why?
|
| Young Adult | 14 | 2024 | 6426 | 0.370 |
Why?
|
| Receptors, Nicotinic | 4 | 2006 | 132 | 0.360 |
Why?
|
| Muscles | 6 | 2004 | 192 | 0.350 |
Why?
|
| Electromyography | 10 | 2011 | 195 | 0.350 |
Why?
|
| Cohort Studies | 10 | 2024 | 2891 | 0.340 |
Why?
|
| Nerve Tissue Proteins | 7 | 2021 | 511 | 0.330 |
Why?
|
| Disorders of Excessive Somnolence | 2 | 2006 | 10 | 0.330 |
Why?
|
| Ion Channel Gating | 3 | 2006 | 329 | 0.330 |
Why?
|
| Rats | 14 | 2022 | 4061 | 0.320 |
Why?
|
| Trinucleotide Repeats | 6 | 2017 | 31 | 0.320 |
Why?
|
| Tremor | 3 | 2019 | 22 | 0.320 |
Why?
|
| Gait | 4 | 2023 | 82 | 0.310 |
Why?
|
| Phenotype | 9 | 2021 | 2473 | 0.300 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 232 | 0.300 |
Why?
|
| Ataxins | 4 | 2018 | 6 | 0.290 |
Why?
|
| Nerve Net | 1 | 2011 | 378 | 0.280 |
Why?
|
| Channelopathies | 1 | 2007 | 4 | 0.280 |
Why?
|
| Neoplasms | 1 | 2022 | 3030 | 0.280 |
Why?
|
| Depression | 4 | 2024 | 517 | 0.280 |
Why?
|
| Nervous System Diseases | 2 | 2008 | 163 | 0.270 |
Why?
|
| Neurologic Examination | 6 | 2012 | 120 | 0.270 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2006 | 28 | 0.270 |
Why?
|
| Quality of Life | 4 | 2024 | 1693 | 0.270 |
Why?
|
| DNA Repeat Expansion | 2 | 2017 | 4 | 0.270 |
Why?
|
| Genotype | 4 | 2021 | 1855 | 0.270 |
Why?
|
| Gait Disorders, Neurologic | 3 | 2023 | 17 | 0.260 |
Why?
|
| Semaphorin-3A | 1 | 2005 | 2 | 0.260 |
Why?
|
| Huntington Disease | 2 | 2014 | 39 | 0.250 |
Why?
|
| Bone Development | 1 | 2005 | 37 | 0.250 |
Why?
|
| Fatigue | 2 | 2024 | 176 | 0.250 |
Why?
|
| Chondrocytes | 1 | 2005 | 65 | 0.250 |
Why?
|
| Positron-Emission Tomography | 3 | 2016 | 340 | 0.240 |
Why?
|
| Observer Variation | 3 | 2025 | 615 | 0.240 |
Why?
|
| Ion Channels | 3 | 2006 | 246 | 0.240 |
Why?
|
| 4-Aminopyridine | 1 | 2024 | 36 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2018 | 1873 | 0.230 |
Why?
|
| Saccades | 4 | 2008 | 68 | 0.230 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 289 | 0.230 |
Why?
|
| Genes, Dominant | 2 | 2003 | 117 | 0.230 |
Why?
|
| Bone and Bones | 1 | 2005 | 273 | 0.230 |
Why?
|
| Fibroblast Growth Factors | 1 | 2024 | 82 | 0.220 |
Why?
|
| Gliadin | 1 | 2004 | 17 | 0.220 |
Why?
|
| Founder Effect | 2 | 2020 | 104 | 0.220 |
Why?
|
| Antibodies | 4 | 2004 | 353 | 0.220 |
Why?
|
| Seizures, Febrile | 1 | 2003 | 25 | 0.220 |
Why?
|
| Brain Mapping | 6 | 2016 | 571 | 0.220 |
Why?
|
| Caspases | 1 | 2004 | 155 | 0.220 |
Why?
|
| Genetics, Medical | 1 | 2004 | 51 | 0.220 |
Why?
|
| Immunoglobulin A | 1 | 2004 | 84 | 0.220 |
Why?
|
| Ophthalmoplegia, Chronic Progressive External | 1 | 2023 | 3 | 0.220 |
Why?
|
| Bell Palsy | 1 | 2023 | 4 | 0.220 |
Why?
|
| Microscopy, Electron | 5 | 2013 | 511 | 0.220 |
Why?
|
| Mitochondria | 4 | 2020 | 562 | 0.220 |
Why?
|
| Biomarkers | 3 | 2023 | 1800 | 0.210 |
Why?
|
| Adolescent | 17 | 2021 | 9354 | 0.210 |
Why?
|
| Oocytes | 7 | 2020 | 219 | 0.210 |
Why?
|
| Clinical Trials as Topic | 4 | 2023 | 1142 | 0.210 |
Why?
|
| Cerebellar Diseases | 3 | 2008 | 21 | 0.210 |
Why?
|
| Family Health | 4 | 2005 | 162 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2021 | 3486 | 0.210 |
Why?
|
| Cell Line | 5 | 2020 | 2505 | 0.210 |
Why?
|
| Nerve Degeneration | 3 | 2015 | 83 | 0.210 |
Why?
|
| Bilateral Vestibulopathy | 1 | 2022 | 3 | 0.210 |
Why?
|
| Motor Activity | 2 | 2016 | 326 | 0.210 |
Why?
|
| Blotting, Western | 2 | 2016 | 795 | 0.210 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2022 | 90 | 0.210 |
Why?
|
| Longitudinal Studies | 5 | 2024 | 1088 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 9 | 1998 | 1397 | 0.210 |
Why?
|
| Time Perception | 3 | 2016 | 24 | 0.210 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 183 | 0.210 |
Why?
|
| Orientation | 2 | 2002 | 119 | 0.210 |
Why?
|
| Immunoglobulin G | 2 | 2004 | 472 | 0.210 |
Why?
|
| Twins, Monozygotic | 1 | 2002 | 58 | 0.210 |
Why?
|
| Vestibular Diseases | 1 | 2022 | 28 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 104 | 0.200 |
Why?
|
| Diseases in Twins | 1 | 2002 | 65 | 0.200 |
Why?
|
| Reflex, Vestibulo-Ocular | 1 | 2002 | 54 | 0.200 |
Why?
|
| Head Movements | 1 | 2002 | 40 | 0.200 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2022 | 67 | 0.200 |
Why?
|
| Psychomotor Performance | 7 | 2011 | 498 | 0.200 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 558 | 0.200 |
Why?
|
| Immunoprecipitation | 2 | 2016 | 140 | 0.200 |
Why?
|
| Neurodegenerative Diseases | 1 | 2022 | 51 | 0.200 |
Why?
|
| Ubiquinone | 2 | 2014 | 10 | 0.200 |
Why?
|
| Aspartic Acid | 3 | 2018 | 64 | 0.190 |
Why?
|
| Consensus | 1 | 2023 | 371 | 0.190 |
Why?
|
| Child, Preschool | 8 | 2021 | 3767 | 0.190 |
Why?
|
| Cell Line, Transformed | 3 | 2013 | 154 | 0.190 |
Why?
|
| Biomedical Research | 1 | 2006 | 403 | 0.190 |
Why?
|
| Space Perception | 1 | 2002 | 117 | 0.190 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 27 | 0.190 |
Why?
|
| Scoliosis | 1 | 2021 | 32 | 0.190 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1806 | 0.180 |
Why?
|
| Peptide Fragments | 2 | 2022 | 465 | 0.180 |
Why?
|
| Basal Ganglia | 2 | 2016 | 46 | 0.180 |
Why?
|
| Pedigree | 6 | 2006 | 969 | 0.180 |
Why?
|
| Child | 14 | 2021 | 7219 | 0.180 |
Why?
|
| Parkinson Disease | 2 | 2021 | 151 | 0.180 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2021 | 46 | 0.180 |
Why?
|
| Prevalence | 5 | 2024 | 1251 | 0.170 |
Why?
|
| Chlorzoxazone | 1 | 2020 | 5 | 0.170 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2020 | 8 | 0.170 |
Why?
|
| Membrane Potentials | 4 | 2011 | 437 | 0.170 |
Why?
|
| Heterozygote | 1 | 2021 | 373 | 0.170 |
Why?
|
| Hydrocephalus | 1 | 2021 | 104 | 0.170 |
Why?
|
| Mental Health Services | 1 | 2020 | 59 | 0.160 |
Why?
|
| DNA Mutational Analysis | 4 | 2020 | 531 | 0.160 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2016 | 324 | 0.160 |
Why?
|
| Transcription Initiation Site | 1 | 2019 | 46 | 0.160 |
Why?
|
| Molecular Sequence Data | 6 | 2012 | 3030 | 0.160 |
Why?
|
| PC12 Cells | 1 | 2019 | 115 | 0.160 |
Why?
|
| Gait Ataxia | 2 | 2010 | 2 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2018 | 315 | 0.160 |
Why?
|
| Analysis of Variance | 5 | 2013 | 898 | 0.160 |
Why?
|
| Autism Spectrum Disorder | 1 | 2020 | 81 | 0.160 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 120 | 0.150 |
Why?
|
| HSP40 Heat-Shock Proteins | 2 | 2015 | 18 | 0.150 |
Why?
|
| Green Fluorescent Proteins | 2 | 2011 | 309 | 0.150 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2018 | 8 | 0.150 |
Why?
|
| Ajmaline | 1 | 2018 | 2 | 0.150 |
Why?
|
| Voltage-Gated Sodium Channel Blockers | 1 | 2018 | 2 | 0.150 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 1 | 2018 | 4 | 0.150 |
Why?
|
| Bungarotoxins | 3 | 2004 | 25 | 0.150 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2018 | 65 | 0.150 |
Why?
|
| Credentialing | 1 | 1997 | 14 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2024 | 9330 | 0.150 |
Why?
|
| Iron-Binding Proteins | 3 | 2012 | 15 | 0.150 |
Why?
|
| Nystagmus, Pathologic | 1 | 1997 | 35 | 0.150 |
Why?
|
| C9orf72 Protein | 1 | 2017 | 18 | 0.150 |
Why?
|
| Dystonia | 1 | 2017 | 29 | 0.150 |
Why?
|
| HeLa Cells | 1 | 2019 | 520 | 0.150 |
Why?
|
| In Vitro Techniques | 2 | 2011 | 997 | 0.140 |
Why?
|
| Apoptosis | 3 | 2013 | 1725 | 0.140 |
Why?
|
| Autistic Disorder | 1 | 2018 | 147 | 0.140 |
Why?
|
| Amino Acid Substitution | 4 | 2012 | 339 | 0.140 |
Why?
|
| Xenopus | 3 | 2020 | 126 | 0.140 |
Why?
|
| Neurons | 5 | 2015 | 1593 | 0.140 |
Why?
|
| Evoked Potentials, Visual | 1 | 1997 | 87 | 0.140 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 2609 | 0.140 |
Why?
|
| Organelles | 1 | 1997 | 57 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 2364 | 0.130 |
Why?
|
| Genetic Therapy | 1 | 2019 | 373 | 0.130 |
Why?
|
| Amino Acid Sequence | 4 | 2012 | 2077 | 0.130 |
Why?
|
| Models, Biological | 2 | 2014 | 1770 | 0.130 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 6816 | 0.130 |
Why?
|
| Growth Hormone | 1 | 2016 | 96 | 0.130 |
Why?
|
| Brain Stem | 4 | 2020 | 167 | 0.130 |
Why?
|
| Corpus Striatum | 1 | 2016 | 89 | 0.130 |
Why?
|
| Genes | 1 | 2016 | 306 | 0.120 |
Why?
|
| alpha Karyopherins | 1 | 2015 | 10 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1935 | 0.120 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2015 | 4 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 285 | 0.120 |
Why?
|
| Walking | 4 | 2022 | 93 | 0.120 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 166 | 0.120 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2015 | 71 | 0.120 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 74 | 0.120 |
Why?
|
| Reaction Time | 4 | 2007 | 312 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 280 | 0.120 |
Why?
|
| Mammals | 1 | 2016 | 245 | 0.120 |
Why?
|
| Fluoxetine | 1 | 2014 | 41 | 0.120 |
Why?
|
| Xenopus laevis | 5 | 2011 | 138 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 4 | 2005 | 923 | 0.120 |
Why?
|
| United States | 3 | 2024 | 7142 | 0.110 |
Why?
|
| Syndrome | 3 | 2022 | 452 | 0.110 |
Why?
|
| Stroke | 1 | 2023 | 1004 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 100 | 0.110 |
Why?
|
| Infant | 4 | 2011 | 3184 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2013 | 12 | 0.110 |
Why?
|
| Synapses | 2 | 2012 | 280 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 1997 | 476 | 0.110 |
Why?
|
| Urinary Incontinence, Urge | 2 | 2011 | 47 | 0.110 |
Why?
|
| Gene Expression | 3 | 2012 | 1313 | 0.110 |
Why?
|
| Neurites | 1 | 2013 | 36 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 34 | 0.110 |
Why?
|
| Gait Apraxia | 1 | 2013 | 1 | 0.110 |
Why?
|
| Comorbidity | 4 | 2016 | 955 | 0.110 |
Why?
|
| Photoreceptor Cells | 1 | 2013 | 21 | 0.110 |
Why?
|
| Pursuit, Smooth | 2 | 2015 | 31 | 0.110 |
Why?
|
| Urodynamics | 2 | 2011 | 123 | 0.110 |
Why?
|
| Protons | 2 | 2010 | 101 | 0.110 |
Why?
|
| Databases, Genetic | 1 | 2014 | 270 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2014 | 305 | 0.100 |
Why?
|
| Vision Disorders | 1 | 2013 | 74 | 0.100 |
Why?
|
| Surveys and Questionnaires | 7 | 2019 | 2670 | 0.100 |
Why?
|
| Action Potentials | 2 | 2011 | 602 | 0.100 |
Why?
|
| Yeasts | 1 | 2012 | 49 | 0.100 |
Why?
|
| Clinical Coding | 1 | 2012 | 24 | 0.100 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 206 | 0.100 |
Why?
|
| Cell Death | 1 | 2013 | 261 | 0.100 |
Why?
|
| Respiratory Mechanics | 1 | 2013 | 102 | 0.100 |
Why?
|
| Acetazolamide | 1 | 2012 | 11 | 0.100 |
Why?
|
| Algorithms | 3 | 2021 | 1919 | 0.100 |
Why?
|
| Neostigmine | 1 | 2011 | 6 | 0.100 |
Why?
|
| Cholinergic Agonists | 1 | 2011 | 11 | 0.100 |
Why?
|
| Plasmids | 1 | 2012 | 292 | 0.100 |
Why?
|
| Sciatic Nerve | 1 | 2011 | 34 | 0.100 |
Why?
|
| Boron Compounds | 1 | 2011 | 20 | 0.100 |
Why?
|
| Carbachol | 1 | 2011 | 36 | 0.100 |
Why?
|
| Post-Synaptic Density | 1 | 2011 | 7 | 0.100 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2011 | 45 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 3278 | 0.100 |
Why?
|
| Electroporation | 1 | 2011 | 58 | 0.100 |
Why?
|
| Base Sequence | 5 | 2011 | 2329 | 0.100 |
Why?
|
| Caribbean Region | 2 | 2022 | 21 | 0.100 |
Why?
|
| Multiple System Atrophy | 1 | 2011 | 4 | 0.090 |
Why?
|
| Shaw Potassium Channels | 1 | 2011 | 8 | 0.090 |
Why?
|
| Anisotropy | 1 | 2011 | 64 | 0.090 |
Why?
|
| Mice, Knockout | 2 | 2013 | 2042 | 0.090 |
Why?
|
| Protein Conformation | 2 | 2012 | 897 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2012 | 253 | 0.090 |
Why?
|
| Neuromuscular Agents | 1 | 2011 | 27 | 0.090 |
Why?
|
| Time Factors | 3 | 2011 | 5366 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2012 | 477 | 0.090 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 84 | 0.090 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2010 | 7 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2012 | 126 | 0.090 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2011 | 50 | 0.090 |
Why?
|
| Exercise Test | 1 | 2011 | 168 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2011 | 298 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2012 | 243 | 0.090 |
Why?
|
| Neuroimaging | 1 | 2012 | 126 | 0.090 |
Why?
|
| Drosophila Proteins | 1 | 2015 | 510 | 0.090 |
Why?
|
| Brain Chemistry | 1 | 2010 | 122 | 0.090 |
Why?
|
| Genetic Linkage | 2 | 2005 | 624 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 1259 | 0.090 |
Why?
|
| Animals, Newborn | 3 | 2020 | 526 | 0.090 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2011 | 90 | 0.090 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 1161 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2011 | 697 | 0.080 |
Why?
|
| Inositol | 3 | 2018 | 16 | 0.080 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2012 | 294 | 0.080 |
Why?
|
| Cell Membrane Permeability | 2 | 2006 | 121 | 0.080 |
Why?
|
| Electrophysiology | 2 | 2008 | 403 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 599 | 0.080 |
Why?
|
| Histones | 1 | 2011 | 344 | 0.080 |
Why?
|
| Histiocytosis | 1 | 2008 | 7 | 0.080 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2008 | 13 | 0.080 |
Why?
|
| Cell Survival | 2 | 2013 | 987 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 728 | 0.080 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 513 | 0.080 |
Why?
|
| DNA | 3 | 2011 | 1314 | 0.080 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2010 | 198 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2008 | 97 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2012 | 1324 | 0.070 |
Why?
|
| Self Medication | 1 | 2007 | 6 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 2007 | 16 | 0.070 |
Why?
|
| Cerebral Cortex | 2 | 2011 | 592 | 0.070 |
Why?
|
| Posture | 3 | 2003 | 125 | 0.070 |
Why?
|
| Calcium Channels, Q-Type | 2 | 2013 | 8 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2008 | 125 | 0.070 |
Why?
|
| Calcium Channels, P-Type | 2 | 2013 | 10 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 1747 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2009 | 192 | 0.070 |
Why?
|
| Kinetics | 4 | 2011 | 1550 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2012 | 666 | 0.070 |
Why?
|
| Perceptual Disorders | 1 | 2007 | 12 | 0.070 |
Why?
|
| Chromosome Mapping | 2 | 2013 | 1074 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2007 | 121 | 0.070 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2006 | 25 | 0.070 |
Why?
|
| Arm | 2 | 2005 | 99 | 0.070 |
Why?
|
| DNA Primers | 2 | 2005 | 546 | 0.070 |
Why?
|
| Transgenes | 2 | 2008 | 185 | 0.070 |
Why?
|
| Basal Ganglia Diseases | 1 | 2006 | 9 | 0.070 |
Why?
|
| Depth Perception | 1 | 2006 | 19 | 0.070 |
Why?
|
| Nuclear Localization Signals | 1 | 2006 | 10 | 0.070 |
Why?
|
| Proteins | 2 | 2021 | 797 | 0.070 |
Why?
|
| Motor Skills | 1 | 2007 | 79 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2006 | 272 | 0.070 |
Why?
|
| Antioxidants | 1 | 2007 | 226 | 0.070 |
Why?
|
| Dysarthria | 1 | 2006 | 6 | 0.070 |
Why?
|
| Genes, Recessive | 2 | 2004 | 86 | 0.070 |
Why?
|
| Amino Acid Motifs | 1 | 2006 | 118 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 78 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 370 | 0.060 |
Why?
|
| Neuropilin-1 | 1 | 2005 | 14 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 429 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 1738 | 0.060 |
Why?
|
| Osteoclasts | 1 | 2005 | 36 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2009 | 367 | 0.060 |
Why?
|
| Antibody Specificity | 2 | 1987 | 130 | 0.060 |
Why?
|
| Thalamic Diseases | 1 | 1985 | 4 | 0.060 |
Why?
|
| Kearns-Sayre Syndrome | 1 | 1985 | 2 | 0.060 |
Why?
|
| Supranuclear Palsy, Progressive | 3 | 1990 | 22 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2020 | 428 | 0.060 |
Why?
|
| Physical Examination | 1 | 2006 | 150 | 0.060 |
Why?
|
| Alleles | 3 | 1998 | 1138 | 0.060 |
Why?
|
| Ophthalmoplegia | 1 | 1985 | 11 | 0.060 |
Why?
|
| Osteoblasts | 1 | 2005 | 97 | 0.060 |
Why?
|
| Femur | 1 | 2005 | 112 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 742 | 0.060 |
Why?
|
| Autoimmune Diseases | 3 | 1985 | 252 | 0.060 |
Why?
|
| Fixation, Ocular | 1 | 2004 | 48 | 0.060 |
Why?
|
| Movement | 3 | 2003 | 315 | 0.060 |
Why?
|
| Cholinesterases | 1 | 2004 | 17 | 0.060 |
Why?
|
| Aminophenols | 1 | 2004 | 4 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2004 | 15 | 0.060 |
Why?
|
| Glutamic Acid | 2 | 2018 | 154 | 0.060 |
Why?
|
| Ligands | 1 | 2005 | 453 | 0.060 |
Why?
|
| Tunisia | 1 | 2004 | 8 | 0.060 |
Why?
|
| Muscle Spasticity | 1 | 2004 | 9 | 0.060 |
Why?
|
| Quebec | 1 | 2004 | 11 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2002 | 284 | 0.060 |
Why?
|
| Turkey | 1 | 2004 | 21 | 0.060 |
Why?
|
| Cell Lineage | 1 | 2005 | 296 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 122 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2004 | 51 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2005 | 446 | 0.060 |
Why?
|
| Italy | 1 | 2004 | 108 | 0.060 |
Why?
|
| Sleep Wake Disorders | 1 | 1985 | 118 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2005 | 385 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2006 | 605 | 0.050 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 2012 | 135 | 0.050 |
Why?
|
| Kinesthesis | 1 | 2003 | 15 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2004 | 692 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 888 | 0.050 |
Why?
|
| Speech Disorders | 3 | 2011 | 19 | 0.050 |
Why?
|
| Japan | 1 | 2004 | 305 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 730 | 0.050 |
Why?
|
| Hand Strength | 1 | 2003 | 53 | 0.050 |
Why?
|
| Hand | 1 | 2004 | 143 | 0.050 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2015 | 59 | 0.050 |
Why?
|
| Glutamine | 1 | 2003 | 81 | 0.050 |
Why?
|
| Executive Function | 1 | 2024 | 96 | 0.050 |
Why?
|
| Rats, Inbred Lew | 5 | 1993 | 197 | 0.050 |
Why?
|
| Rotation | 1 | 2002 | 91 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2004 | 697 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 35 | 0.050 |
Why?
|
| Physical Stimulation | 1 | 2002 | 72 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 104 | 0.050 |
Why?
|
| Permeability | 1 | 2002 | 138 | 0.050 |
Why?
|
| Models, Neurological | 2 | 2002 | 412 | 0.050 |
Why?
|
| Gene Targeting | 1 | 2002 | 74 | 0.050 |
Why?
|
| Feedback | 1 | 2002 | 135 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2024 | 236 | 0.050 |
Why?
|
| Penetrance | 1 | 2021 | 46 | 0.050 |
Why?
|
| Neurogenesis | 1 | 2022 | 78 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2002 | 286 | 0.050 |
Why?
|
| Presynaptic Terminals | 1 | 2001 | 41 | 0.050 |
Why?
|
| Functional Laterality | 2 | 2013 | 199 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 318 | 0.050 |
Why?
|
| Microsurgery | 1 | 2021 | 91 | 0.050 |
Why?
|
| Neurotransmitter Agents | 1 | 2001 | 108 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2895 | 0.040 |
Why?
|
| Ataxin-2 | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ataxin-10 | 1 | 2020 | 1 | 0.040 |
Why?
|
| Ataxin-3 | 1 | 2020 | 3 | 0.040 |
Why?
|
| Cuba | 1 | 2020 | 5 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2015 | 4348 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2000 | 17 | 0.040 |
Why?
|
| Ubiquitins | 1 | 2000 | 38 | 0.040 |
Why?
|
| Mexico | 1 | 2020 | 70 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 77 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 120 | 0.040 |
Why?
|
| Dependovirus | 1 | 2020 | 34 | 0.040 |
Why?
|
| Ligases | 1 | 2000 | 46 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 46 | 0.040 |
Why?
|
| Excitatory Postsynaptic Potentials | 2 | 2013 | 88 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2010 | 234 | 0.040 |
Why?
|
| Condoms, Female | 1 | 1999 | 2 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 252 | 0.040 |
Why?
|
| Memory Disorders | 2 | 1989 | 69 | 0.040 |
Why?
|
| Research Design | 1 | 2022 | 590 | 0.040 |
Why?
|
| Women | 1 | 1999 | 25 | 0.040 |
Why?
|
| Mental Health | 1 | 2020 | 181 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2020 | 446 | 0.040 |
Why?
|
| Phrenic Nerve | 1 | 1998 | 42 | 0.040 |
Why?
|
| Genomic Imprinting | 1 | 1998 | 32 | 0.040 |
Why?
|
| Caregivers | 1 | 2020 | 170 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 1998 | 82 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1015 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 201 | 0.040 |
Why?
|
| Lod Score | 1 | 1997 | 152 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2018 | 85 | 0.040 |
Why?
|
| Binding Sites | 2 | 2000 | 1127 | 0.040 |
Why?
|
| Attitude to Health | 1 | 1999 | 220 | 0.040 |
Why?
|
| Neurotoxins | 1 | 1997 | 49 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 303 | 0.040 |
Why?
|
| Eye Movements | 1 | 1997 | 118 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 440 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2008 | 103 | 0.030 |
Why?
|
| Disability Evaluation | 2 | 2008 | 140 | 0.030 |
Why?
|
| Synaptic Membranes | 1 | 1996 | 14 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 1462 | 0.030 |
Why?
|
| Curare | 1 | 1996 | 3 | 0.030 |
Why?
|
| Codon | 1 | 1996 | 123 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 1999 | 316 | 0.030 |
Why?
|
| Gene Amplification | 1 | 1996 | 135 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 28 | 0.030 |
Why?
|
| alpha-Synuclein | 1 | 2015 | 20 | 0.030 |
Why?
|
| Leucine | 1 | 1995 | 60 | 0.030 |
Why?
|
| Phenylalanine | 1 | 1995 | 36 | 0.030 |
Why?
|
| tau Proteins | 1 | 2015 | 78 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 427 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2015 | 183 | 0.030 |
Why?
|
| Psychophysics | 2 | 2006 | 80 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2005 | 3431 | 0.030 |
Why?
|
| Epitopes | 3 | 1991 | 254 | 0.030 |
Why?
|
| White Matter | 1 | 2015 | 85 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1999 | 537 | 0.030 |
Why?
|
| Myelin Basic Protein | 2 | 1991 | 50 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1216 | 0.030 |
Why?
|
| Alternative Splicing | 2 | 2008 | 214 | 0.030 |
Why?
|
| Calbindins | 1 | 2013 | 19 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2015 | 319 | 0.030 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2013 | 22 | 0.030 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2013 | 36 | 0.030 |
Why?
|
| Ethylnitrosourea | 1 | 2013 | 30 | 0.030 |
Why?
|
| Alkylating Agents | 1 | 2013 | 32 | 0.030 |
Why?
|
| Physostigmine | 2 | 1990 | 19 | 0.030 |
Why?
|
| Genome | 1 | 1996 | 393 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 145 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 57 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2013 | 135 | 0.030 |
Why?
|
| Contrast Sensitivity | 1 | 2013 | 70 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2013 | 202 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1996 | 827 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2013 | 141 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2013 | 203 | 0.020 |
Why?
|
| Visual Perception | 1 | 2015 | 327 | 0.020 |
Why?
|
| Photic Stimulation | 2 | 2006 | 503 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 282 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2011 | 64 | 0.020 |
Why?
|
| Muscarinic Antagonists | 1 | 2011 | 59 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2015 | 544 | 0.020 |
Why?
|
| Acute Disease | 3 | 1993 | 854 | 0.020 |
Why?
|
| Isoprostanes | 1 | 2010 | 3 | 0.020 |
Why?
|
| Ataxin-7 | 2 | 2002 | 5 | 0.020 |
Why?
|
| Phosphocreatine | 1 | 2010 | 13 | 0.020 |
Why?
|
| Speech Perception | 1 | 2011 | 72 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 282 | 0.020 |
Why?
|
| Creatine | 1 | 2010 | 25 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2015 | 615 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2010 | 119 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 1990 | 74 | 0.020 |
Why?
|
| Ultrasonics | 1 | 1990 | 39 | 0.020 |
Why?
|
| Prognosis | 2 | 2009 | 3813 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2011 | 355 | 0.020 |
Why?
|
| Minority Health | 1 | 2009 | 10 | 0.020 |
Why?
|
| Actins | 1 | 2013 | 469 | 0.020 |
Why?
|
| Florida | 1 | 2009 | 60 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1990 | 132 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2010 | 189 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1990 | 145 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2010 | 1727 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2002 | 591 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2000 | 565 | 0.020 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 1988 | 61 | 0.020 |
Why?
|
| Poverty | 1 | 2009 | 187 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2007 | 31 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 526 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1987 | 42 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1990 | 722 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 328 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 595 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2007 | 89 | 0.020 |
Why?
|
| Illusions | 1 | 2006 | 12 | 0.020 |
Why?
|
| Random Allocation | 1 | 2007 | 327 | 0.020 |
Why?
|
| Gangliosidoses | 1 | 1986 | 1 | 0.020 |
Why?
|
| G(M2) Ganglioside | 1 | 1986 | 3 | 0.020 |
Why?
|
| Gangliosides | 1 | 1986 | 10 | 0.020 |
Why?
|
| Speech Production Measurement | 1 | 2006 | 9 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2006 | 66 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1500 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1988 | 407 | 0.020 |
Why?
|
| Hemagglutination Tests | 1 | 1985 | 11 | 0.020 |
Why?
|
| Binding Sites, Antibody | 1 | 1985 | 49 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 198 | 0.020 |
Why?
|
| Judgment | 1 | 2006 | 68 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 795 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1985 | 146 | 0.020 |
Why?
|
| Smoking | 1 | 2009 | 627 | 0.020 |
Why?
|
| Peripheral Nerves | 1 | 2005 | 37 | 0.020 |
Why?
|
| Registries | 1 | 2009 | 812 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 270 | 0.010 |
Why?
|
| Leg | 1 | 2005 | 140 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2007 | 462 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1991 | 1229 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 682 | 0.010 |
Why?
|
| Acetylcholinesterase | 1 | 1983 | 48 | 0.010 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 1983 | 21 | 0.010 |
Why?
|
| Chickens | 1 | 1983 | 212 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 1871 | 0.010 |
Why?
|
| Macrophages | 1 | 1985 | 585 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 8379 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2003 | 482 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 2019 | 0.010 |
Why?
|
| Hydroxymercuribenzoates | 1 | 2000 | 1 | 0.010 |
Why?
|
| Sulfhydryl Reagents | 1 | 2000 | 8 | 0.010 |
Why?
|
| Anaphase-Promoting Complex-Cyclosome | 1 | 2000 | 16 | 0.010 |
Why?
|
| Mercuric Chloride | 1 | 2000 | 9 | 0.010 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2000 | 30 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1981 | 143 | 0.010 |
Why?
|
| Immunization, Passive | 2 | 1993 | 71 | 0.010 |
Why?
|
| Rabbits | 1 | 2000 | 641 | 0.010 |
Why?
|
| Cysteine | 1 | 2000 | 145 | 0.010 |
Why?
|
| San Francisco | 1 | 1999 | 24 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2000 | 174 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 5583 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 3698 | 0.010 |
Why?
|
| Homozygote | 1 | 1998 | 200 | 0.010 |
Why?
|
| Models, Immunological | 1 | 1998 | 81 | 0.010 |
Why?
|
| Sexual Partners | 1 | 1999 | 102 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2000 | 1242 | 0.010 |
Why?
|
| Joints | 1 | 1997 | 33 | 0.010 |
Why?
|
| Oculomotor Muscles | 1 | 1997 | 29 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 662 | 0.010 |
Why?
|
| Reference Standards | 1 | 1997 | 143 | 0.010 |
Why?
|
| Clone Cells | 2 | 1991 | 215 | 0.010 |
Why?
|
| Communication | 1 | 1999 | 462 | 0.010 |
Why?
|
| Incidence | 1 | 1998 | 1594 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1991 | 38 | 0.010 |
Why?
|
| Art | 1 | 1990 | 5 | 0.010 |
Why?
|
| Concept Formation | 1 | 1990 | 18 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1991 | 120 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1991 | 142 | 0.010 |
Why?
|
| Thinking | 1 | 1990 | 35 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1991 | 320 | 0.010 |
Why?
|
| Hybridomas | 1 | 1988 | 75 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1990 | 264 | 0.000 |
Why?
|
| Immunization | 1 | 1988 | 163 | 0.000 |
Why?
|
| Affect | 1 | 1990 | 390 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1988 | 695 | 0.000 |
Why?
|
| Hexosaminidases | 1 | 1986 | 7 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1991 | 741 | 0.000 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1985 | 44 | 0.000 |
Why?
|
| Attention | 1 | 1990 | 399 | 0.000 |
Why?
|
| Cognition | 1 | 1990 | 588 | 0.000 |
Why?
|
| Leukocytes | 1 | 1986 | 209 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1988 | 553 | 0.000 |
Why?
|
| Autoantibodies | 1 | 1985 | 275 | 0.000 |
Why?
|
| Hybrid Cells | 1 | 1980 | 71 | 0.000 |
Why?
|
| Myeloma Proteins | 1 | 1980 | 37 | 0.000 |
Why?
|
| Inflammation | 1 | 1985 | 990 | 0.000 |
Why?
|